Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Protonix (pantoprazole sodium) For Delayed-Release Oral Suspension and Delayed-Release Tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – May 2012

 

Summary View

 

5 WARNINGS AND PRECAUTIONS

5.8 Concomitant use of PROTONIX with Methotrexate
  • Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose .....

7 DRUG INTERACTIONS

7.6 Methotrexate
  • Case reports, published population suggest that concomitant administration of PPIs and methotrexate .....
-
-